secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009738
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm reports prelim FY2025 total revenue ~$145M; cash ~$64M; Phase 3 myelofibrosis data due March 2026
--------------------------------------------------------------------------------

- Preliminary total revenue for 2025 ~$145M; Q4 2025 ~$33M. U.S. XPOVIO net product revenue 2025 ~$115M; Q4 ~$32M.
- Cash and investments as of Dec 31, 2025 ~$64M; liquidity expected to fund operations into Q2 2026.
- Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026; XPORT-EC-042 endometrial cancer data due mid-2026.
- Completed strategic financing transactions to extend cash runway beyond SENTRY readout.
- Global patient access expanded: selinexor approved in >50 countries; reimbursement in Spain and China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/0001193125-26-009738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer